Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to evaluate non-inferiority of pramipexole Extended release to
Immediate release at 18 weeks on the primary efficacy endpoint (Unified Parkinson's Disease
Rating Scale II+III) in Chinese PD patients who can be concomitantly treated with Levodopa .